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Abstract
Background: The High Resolution Melting (HRM) technology has recently been introduced as a rapid and robust
analysis tool for the detection of DNA methylation. The methylation status of multiple tumor suppressor genes
may serve as biomarkers for early cancer diagnostics, for prediction of prognosis and for prediction of response
to treatment. Therefore, it is important that methodologies for detection of DNA methylation continue to
evolve. Sensitive Melting Analysis after Real Time - Methylation Specific PCR (SMART-MSP) and Methylation
Sensitive - High Resolution Melting (MS-HRM) are two methods for single locus DNA methylation detection
based on HRM.
Methods: Here, we have assessed the quality of DNA extracted from up to 30 years old Formalin Fixed Paraffin
Embedded (FFPE) tissue for DNA methylation analysis using SMART-MSP and MS-HRM. The quality assessment
was performed on DNA extracted from 54 Non-Small Cell Lung Cancer (NSCLC) samples derived from FFPE
tissue, collected over 30 years and grouped into five years intervals. For each sample, the methylation levels of
the CDKN2A (p16) and RARB promoters were estimated using SMART-MSP and MS-HRM assays designed to
assess the methylation status of the same CpG positions. This allowed for a direct comparison of the methylation
levels estimated by the two methods for each sample.
Results: CDKN2A promoter methylation levels were successfully determined by SMART-MSP and MS-HRM in all
54 samples. Identical methylation estimates were obtained by the two methods in 46 of the samples. The
methylation levels of the RARB promoter were successfully determined by SMART-MSP in all samples. When using
MS-HRM to assess RARB methylation five samples failed to amplify and 15 samples showed a melting profile
characteristic for heterogeneous methylation. Twenty-seven of the remaining 34 samples, for which the
methylation level could be estimated, gave the same result as observed when using SMART-MSP.
Conclusion: MS-HRM and SMART-MSP can be successfully used for single locus methylation studies using DNA
derived from up to 30 years old FFPE tissue. Furthermore, it can be expected that MS-HRM and SMART-MSP will
provide similar methylation estimates when assays are designed to analyze the same CpG positions.
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Background
More than two decades of research have identified DNA
methylation of the carbon-5 position of cytosine residues
followed by guanine (CpG dinucleotides) as a very impor-
tant epigenetic mechanism involved in the development
of human cancer. Numerous tumor suppressor genes
undergo de novo methylation and silencing in various can-
cers despite an overall reduced methylation content of the
cancer genome. These changes have shown to be widely
implicated in the development and progression of human
cancers [1]. Furthermore, the aberrant methylation events
take place early in tumorigenesis, and may therefore be
used as a potential biomarker for early cancer detection
[2].
A sufficient number of clinical samples of high DNA qual-
ity are often unavailable for retrospective studies involv-
ing DNA methylation biomarkers and studies of other
clinically important questions relating to DNA methyla-
tion. On the other hand, DNA samples from Formalin
Fixed Paraffin Embedded (FFPE) tissue are often abun-
dant and have been stored for decades. However, the use
of DNA from old FFPE tissue may be problematic as the
DNA is often degraded and only limited amounts may be
available. Furthermore, sodium bisulfite treatment [3],
preserving methylation marks, and as such necessary for
PCR-based studies of DNA methylation, may further
degrade the DNA.
Many different PCR-based methods for the detection of
DNA methylation have been developed [4]. Methylation
specific PCR (MSP) [5] is the most widely used as it is very
sensitive, cost-effective, and does not require specialized
equipment. However, MSP has several drawbacks. First, it
is a non-quantitative method. Measurement of the meth-
ylation level in a sample may be relevant, since low-level
methylation may not be associated with transcriptional
silencing [6]. Second, MSP is prone to false-positive
results [7-9]. Third, MSP is not a closed-tube method,
which increases the risk of PCR contamination. In a tech-
nique called MethyLight [10], the use of TaqMan probes
located in between the MSP primers allow for methyla-
tion levels to be estimated. This, however, increases the
costs of the experiments.
The second range of PCR-based methods, used in locus
specific methylation studies, amplifies the DNA template
regardless of its methylation status, which can be analyzed
post-PCR by a variety of different platforms [3,11-14].
However, it is often difficult to achieve a methylation-
independent PCR amplification due to the PCR bias phe-
nomenon, which is described as preferential amplifica-
tion of unmethylated templates [15,16].
In collaboration with A. Dobrovic and colleagues, we
have recently developed two methods for the analysis of
DNA methylation aiming at overcoming some of the
problems of previously described methodologies. Both
methods utilize the High-Resolution Melting (HRM)
technology [17]. The first, Methylation-Sensitive HRM
(MS-HRM) [18,19], relies on primers designed to amplify
the target independent of its methylation status. The sec-
ond, Sensitive Melting Analysis after Real Time - Methyla-
tion Specific PCR (SMART-MSP) [7], utilizes primers
designed to amplify only methylated templates as is the
case for MSP and MethyLight. SMART-MSP allows quanti-
fying methylation levels in a cost-effective manner, by
using intercalation dyes instead of fluorescent probes.
Furthermore, SMART-MSP allows some false-positive
results to be excluded from the experiments via HRM
analysis, which is an integral part of the protocol [7]. Both
methods have shown to be highly sensitive, and allow
estimation of the methylation levels in the samples [7,18].
Estimation of methylation levels in MS-HRM is per-
formed on the basis of a comparison of melting profiles of
screened samples and standards of known ratios of meth-
ylated and unmethylated DNA, whereas in SMART-MSP
the real-time PCR data are used to quantify methylation
levels. The main feature of MS-HRM, as described by Woj-
dacz and Dobrovic [20], is that it allows controlling of the
PCR bias during methylation-independent PCR amplifi-
cation. This is achieved by including a limited number of
CpG sites in the primers and optimizing the annealing
temperature [16,20]. The same real-time PCR and HRM
instrument and reagents are used for both methods facili-
tating independent result verifications.
We have assessed the quality of DNA extracted from archi-
val Non-Small Cell Lung Cancer (NSCLC) FFPE tissue for
DNA methylation analysis using the SMART-MSP and MS-
HRM methodologies. SMART-MSP and MS-HRM assays
were designed to analyze the same CpG positions to allow
a direct comparison of the methylation level of the sam-
ples, dating 5 - 30 years back in time. The methylation sta-
tus of the CDKN2A  (p16) and RARB  promoter CpG
islands were analyzed. Variation amongst replicates and
amongst bisulfite modifications was evaluated. Further-
more, immunohistochemical staining for the p16 protein
was performed and correlated to the methylation status of
the samples.
Methods
Samples and DNA Extraction
FFPE blocks from 54 Non-Small Cell Lung Cancer
(NSCLC) patients were selected from the archives of the
Institute of Pathology, Aarhus University Hospital. Seven
samples were 30 years old, eight samples were 25 years
old, 13 samples were 20 years old, 10 samples were 15
years old, 10 samples were 10 years old, and six samples
were five years old. Blocks containing large areas of carci-
noma infiltration were selected. For each sample, four tis-
sue sections of 10 μm were transferred into aBMC Cancer 2009, 9:453 http://www.biomedcentral.com/1471-2407/9/453
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microcentrifuge tube and incubated in 1.5 ml of xylene
for 30 min at 37°C. After centrifugation at 14,000 rpm for
3 min, the supernatant was removed. This step was
repeated once. Subsequently, the tissue samples were
washed in 1 ml of 99% ethanol. After centrifugation at
7200 rpm for 3 min the supernatant was discharged. The
washing procedure was repeated twice. The samples were
air dried at ambient temperature for 30 min. DNA was
extracted using the MagNA Pure LC (Roche Molecular Bio-
chemicals, Penzberg/Germany), a semi-automatic system
for isolation of nucleic acids utilizing magnetic bead tech-
nology. The purification was done according to the man-
ufacture's instructions.
DNA was extracted from peripheral blood (PB) obtained
from medical students of both sexes in their first year at
Medical school, following a modified salt precipitation
protocol as previously described [21].
The Local Ethical Committee, Aarhus County, Denmark,
approved this study.
Stereological analysis
In order to estimate the amount of tumor tissue and
necrosis in the sections and to detect if low level of meth-
ylation were due to low amount of vital tumor, we chose
to determine the area fraction (AF) of these two compo-
nents. The stereological analysis was performed using a
light microscope equipped with a computer assisted ster-
eology system (CAST, Olympus, Denmark). The counting
frame covered an area of 8,320 μm and the sampling was
done in a systematic, random fashion. A median number
of 18 (range 5-26) and 20 (range 4-40) counting frames
were evaluated for vital tumor and necrosis, respectively.
The AF staining positive for vital tumor and necrosis was
determined by point-counting [22] at a magnification of
× 739. Points hitting artifacts were not considered.
Preparation of control samples
Universal methylated DNA (Chemicon, Millipore, Biller-
ica, MA) was subjected to bisulfite modification as
described below and used as a methylation positive con-
trol for the SMART-MSP and MS-HRM assays. DNA
extracted from PB was subjected to whole genome ampli-
fication (WGA) for creation of an unmethylated control.
The WGA was performed as previously described [7], in
which the primary WGA product was subjected to a sec-
ond round of WGA. The secondary WGA product was sub-
jected to bisulfite modification, as described below, and
used as an unmethylated control. A standard dilution
series, of 100%, 10%, 1%, and 0.1% methylated DNA in
a background of unmethylated DNA, was prepared by
serially diluting the methylation positive control into the
unmethylated control. These standards were used for
assessing the sensitivity of the SMART-MSP and MS-HRM
assays, and for melting profile comparisons with the sam-
ples in MS-HRM. For the SMART-MSP assays the standard
dilution series were, in addition, used to assess the quan-
titative accuracy and the PCR efficiency of the assays using
the LightCycler 480 Software Version 1.5.
Sodium Bisulfite Treatment
Five hundred nanograms of genomic DNA was subjected
to sodium bisulfite treatment with the EpiTect® Bisulfite
kit (Qiagen, Hilden, Germany) according to the manufac-
turer's instructions.
MS-HRM and SMART-MSP primer design
MS-HRM primers were designed to be methylation inde-
pendent according to the guidelines given in [20], and the
SMART-MSP primers were designed to be methylation
specific according to the guidelines given in [7]. The
SMART-MSP assays were designed to assess the same CpG
positions as the MS-HRM assays (Figure 1) to allow for a
direct comparison of the methylation levels estimated by
the two methods. For this reason, it was not possible to
include CpG sites between the SMART-MSP primers to
allow for the detection of false positive results due to false
priming events as described [7]. Both SMART-MSP assays
have one non-CpG cytosine between the primers. The
conversion status of these cytosines can be assessed by the
HRM analysis, and a right-shifted melting profile indicate
that the observed amplification may be due to incomplete
conversion of unmethylated cytosines [7]. The primer
sequences and genomic regions spanned, as well as ampli-
con sizes and the annealing temperatures (TA) are listed in
Table 1.
SMART MSP control assay
In SMART-MSP a control assay was used to normalize for
DNA input in the reactions as DNA concentrations cannot
be measured directly after bisulfite modification. We have
used a control assay based on Alu sequences depleted of
CpG sites by evolutionary deamination previously
described [23]. This assay is less susceptible to normaliza-
tion errors caused by aneuploidy and copy number
changes often observed in cancer cells, and is especially
suitable for determining relative DNA amounts in sam-
ples where the quantity and/or quality may be limited
[23]. Here, this assay was successfully applied for SMART-
MSP quantification without the TaqMan probe using an
intercalating fluorescent dye instead.
PCR and HRM Conditions
PCR cycling and HRM analysis were performed on the
LightCycler®  480 (Roche Applied Science, Mannheim,
Germany). The reaction mixtures consisted of 20 ng of
bisulfite modified DNA using the LC480 HRM Scanning
Master (Roche) with primer concentrations of 200 nmol/
l of each primer and a final MgCl2 concentration of 3BMC Cancer 2009, 9:453 http://www.biomedcentral.com/1471-2407/9/453
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mmol/l in a total volume of 10 μl. The cycling protocol
started with one cycle of 95°C for 10 minutes for enzyme
activation followed by 45 cycles of 95°C for 5 seconds, TA
(Table 1) for 10 seconds, 72°C for 10 seconds, one cycle
of 95°C for 1 minute, one cycle of 65°C for 1 minute and
a melt from 65 to 95°C for all assays. In the ALU control
assay the PCR cycling steps was performed for 10, 20, 20
seconds instead of 5, 10, 10 seconds. The melting step was
performed using 30 acquisitions per °C. For the MS-HRM
assays the annealing temperatures were experimentally
determined for each assay to ensure that the 0.1% meth-
ylated standard could be detected. For the SMART-MSP
assays the annealing temperatures were experimentally
determined for each assay to ensure that only methylated
templates were amplified. All samples were analyzed in
triplicate.
MS-HRM and SMART-MSP data analysis
In MS-HRM, the methylation levels of each sample were
assessed by comparison of the PCR product melting pro-
files between each sample and the standards with known
ratio of methylated and unmethylated templates as
described [18]. Here, the melting profiles of samples were
compared to melting profiles of PCR products derived
from mixes of 100%, 10%, 1%, 0.1% and 0% of fully
methylated template in an unmethylated background,
and scored as being methylated at low level (0.1-1%)
medium level (1-10%) or high level (10-100%). The sam-
ples were scored as being heterogeneously methylated if a
melting profile characteristic for the amplification of mol-
ecules of different methylation content was observed as
previously described [13,24].
In SMART-MSP, the relative methylation levels in the sam-
ples were estimated relative to universal methylated DNA
(Chemicon) using the 2-ΔΔCt real-time PCR quantification
approach ()[25], as described in [7] in which ΔΔCt =
unknown sample (Cttarget gene - CtALU control) - 100% meth-
ylated DNA (Cttarget gene - CtALU control). This approach
implies that the methylation assays have approximately
the same E as the control assay ()[25]. The HRM profiles
of the samples were compared to the melting profile of
universal methylated DNA (Chemicon) and results were
discarded if a deviation of more than 0.5ΔC was observed.
The melting temperature of each assay was approximately
80.3°C for CDKN2A and 77.4°C for RARB.
The samples were analyzed in triplicates in order to assess
if the reproducibility amongst replicates of the SMART-
MSP assays decreased with the age of the samples. For this
purpose, three different methylation estimates were calcu-
lated from the individual Ct-values of the triplicates of
each sample in the control assay and the respective meth-
ylation assay. The first value is the lowest possible meth-
ylation estimate that can be calculated from the Ct-values
(using the highest Ct-value of the methylation assay and
the lowest Ct-value of the control assay of the triplicates).
The second value is calculated from the average Ct-value
of the triplicates, whereas the third value is the highest
possible value that can be calculated from the Ct-values
(using the lowest Ct-value of the methylation assay and
the highest Ct-value of the control assay).
In MS-HRM, at least two of the three replicates of a sample
need to give the same result (methylation positive or
methylation negative) for the methylation level to be
determined. For both methods, samples were scored as
"failed amplification" when only one or none of the three
replicates amplified.
The sensitivity and quantitative accuracy of the assays
A standard dilution series from 100% to 0.1% methylated
DNA was used to assess the sensitivity of the CDKN2A and
RARB SMART-MSP and MS-HRM assays (Figure 2).
In addition, the standard dilution series was used for the
SMART-MSP assays to assess the quantitative accuracy and
the PCR efficiency of each assay.
Based on the standard curve the LC480 software measures
an  Error  value (mean squared error of the single data
points fit to the regression line). The Error value is a meas-
urement of the quantitative accuracy of the assays. An
The design of the CDKN2A and RARB SMART-MSP and MS- HRM assays Figure 1
The design of the CDKN2A and RARB SMART-MSP 
and MS-HRM assays. The SMART-MSP assays were 
designed to analyze the same CpG positions as the MS-HRM 
assays to allow for a direct comparison of the methylation 
levels in the samples. The MS-HRM primers are denoted as 
green arrows and the SMART-MSP primers as orange 
arrows. The CpG positions are denoted as lollipops.BMC Cancer 2009, 9:453 http://www.biomedcentral.com/1471-2407/9/453
Page 5 of 11
(page number not for citation purposes)
acceptable Error value should be less than 0.2 according to
the LightCycler 480 Instrument Operator's Manual. The
Error value for the CDKN2A assay was 0.13, the Error value
for the RARB assay was 0.10, and the Error value for the
ALU control assay was 0.13.
The LC480 software was also used to calculate the PCR
efficiency (E) from the standard curve for each of the
SMART-MSP assays. The E  value for each assay was:
CDKN2A = 2.01, RARB = 2.07, and ALU Control = 2.02.
Immunohistochemistry
Sections of fixed paraffin-embedded tissue were dewaxed
in xylene and rehydrated in graded alcohol. Endogenous
peroxidase activity was blocked by 0.5 per cent H2O2 in
absolute methanol for 10 min at room temperature. To
reveal antigen, the sections were pretreated by boiling in
target reveal solution (DAKO, Denmark) using a micro-
wave oven. Non-specific binding of immunoglobulin was
quenched by incubating the sections in 10 per cent goat
serum for 20 min. Sections were incubated with a 1:50
diluted mouse-antihuman monoclonal p16 antibody
(clone G175-405, monoclonal mouse IgG; Pharmingen,
San Diego, CA). Antigen - antibody reaction was detected
by incubation with EnVisionTM+ Dual Link System-HRP
(DAKO, Denmark). The peroxidase activity was visualized
by 0.05 per cent 3,3-diaminobenzidine tetrahydro-chlo-
ride (Kem-En-Tek, Denmark) dissolved in PBS containing
0.1 percent H2O2. Counterstaining was carried out using
Mayer's haematoxylin. Finally, the sections were dehy-
drated in graded alcohol and mounted in hydrophobic
mounting media. Negative controls were obtained after
incubation of the sections in PBS instead of primary anti-
bodies. Reactive lymphocytes and inflammatory cells
served as positive internal controls. A tumor was consid-
ered positive if 5% of the nuclei showed nuclear staining.
Results
Methylation analysis of the FFPE samples
The methylation levels of the CDKN2A and RARB pro-
moters in 54 FFPE NSCLC samples, stored between 1978
and 2003, were estimated by the MS-HRM and SMART-
MSP assays. The estimates of the methylation levels are
given in Table 2. As described in the methods section three
different methylation estimates were calculated for each
sample when using SMART-MSP to evaluate the variation
between replicates. The integrity of the DNA was sufficient
for all samples showing 0% methylation in the SMART-
MSP assays, as all of these samples amplified in the ALU
control assay.
For CDKN2A we could successfully determine the methyl-
ation levels of all 54 samples using both methods. In 46
of the 54 samples the average SMART-MSP methylation
estimate (second column within the SMART-MSP column
in Table 2) was within the range estimated by MS-HRM.
This is unlikely to have occurred by chance (Binomial test,
p-value 1.384 × 10-7).
Methylation levels for RARB were successfully determined
when using SMART-MSP of all 54 samples. Five samples
failed to amplify when using MS-HRM. The MS-HRM
results indicated that heterogeneously methylated mole-
cules were amplified in 15 of the samples. An example of
a heterogeneously methylated sample is shown in figure
3. All of the heterogeneously methylated samples were
estimated to be methylated at low levels (0%-3.6%) by
SMART-MSP. Twenty-seven of the remaining 34 samples
had an average SMART-MSP methylation estimate (sec-
ond column within the SMART-MSP column in Table 2)
within the range estimated by MS-HRM. This is unlikely to
have occurred by chance (Binomial test, p-value
0.0008214).
Table 1: Primer sequences, annealing temperatures, and amplicon information for the MS-HRM and SMART-MSP assays (UCSC 
Genome Browser, August 2008).
Gene Primer sequences (CpG sites 
underlined and converted Cs 
as capital Ts or As). (5'→ 3').
Annealing 
temperature

































62°C 98 bp N/A Consensus seq., See 
ref [23].BMC Cancer 2009, 9:453 http://www.biomedcentral.com/1471-2407/9/453
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To evaluate if the reproducibility of the methylation esti-
mates amongst replicates was dependent on the age of the
samples, we plotted the absolute difference between the
highest and lowest possible methylation estimate divided
by the average methylation estimate against the age of the
samples for each gene (Figure 4). From these plots, it was
concluded that the reproducibility of the SMART-MSP
assays did not decrease with the age of the samples. In
general, the reproducibility was better for the CDKN2A
SMART-MSP assay compared to the RARB SMART-MSP
assay.
Percentage of tumor tissue and necrosis versus 
methylation level
The amount of tumor tissue and necrosis in the sections
were determined in order to evaluate if low level of meth-
ylation were due to low amount of vital tumor or influ-
enced by the amount of necrosis. However, we found no
difference in area of necrosis or vital tumor between the
tumors with low, medium or high level of methylation
(data not shown). This may be due to the fact that meth-
ylation of both CDKN2A and RARB can be detected in
adjacent normal lung tissue [26].
Immunohistochemistry
It is well known that the quality of old FFPE samples is
sufficient for immunohistochemistry to be performed.
Therefore, we evaluated whether the immunohistochemi-
cal staining of the p16 protein correlated with methyla-
tion status of the CDKN2A (p16) gene. An example of a
positive and a negative sample is shown in figure 5, and
the results can be found in table 2. Immunohistochemis-
try results were available for all samples except two. Eight-
een of the 20 methylated samples for which
immunohistochemistry results were available were nega-
tive. The two methylated samples that were positive by
immunohistochemistry were only found to be methylated
at very low levels (0.1%-1% by MS-HRM as well as by
SMART-MSP). Of the 30 unmethylated samples for which
immunohistochemistry results were available 18 samples
were positive. Thus, an association between methylation
and immunohistochemical staining was found (Pearson's
The sensitivity of the CDKN2A and RARB SMART-MSP and MS-HRM assays Figure 2
The sensitivity of the CDKN2A and RARB SMART-MSP and MS-HRM assays. The sensitivity of the assays was tested 
using standard dilution series of methylated DNA into unmethylated DNA. The 100% methylated standards are indicated in 
red, the 10% methylated standards in blue, the 1% methylated standards in green, the 0.1% methylated standards in brown, the 
0% methylated standard in orange and non template controls are indicated in black. A. The CDKN2A SMART-MSP assay (real-
time amplification data). B. The CDKN2A MS-HRM assay (normalized melting curves). C. The RARB SMART-MSP assay (real-
time amplification data). D. The RARB MS-HRM assay (normalized melting curves). All assays successfully detect 0.1% methyla-
tion.BMC Cancer 2009, 9:453 http://www.biomedcentral.com/1471-2407/9/453
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Table 2: Methylation levels of the samples as estimated by MS-HRM and SMART-MSP. 
Methylation levels estimated for CDKN2A Methylation levels estimated for RARB
Sample Immunohistochemistry 
for p16













1 (1978) Negative 0.1%-1% 1.7% 2.7% 3.4% Failed ampl 0% 0% 0%






0.1%-1% 0% 0% 0%






Het met 0% 0% 0%






1%-10% 2.4% 9.5% 30.8%






10%-100% 14.4% 20.3% 28.7%






0.1%-1% 0.1% 0.3% 0.4%






0% 0% 0% 0%
8 (1978) No data 10%-100% 20.3% 25.0% 28.7% 10%-100% 57.4% 61.6% 75.8%
9 (1983) Negative 1%-10% 0.7% 1.9% 5.4% Failed ampl 4.1% 5.8% 7.2%
10 (1983) Positive 0% 0% 0% 0% 10%-100% 21.8% 26.8% 33.0%
11 (1983) Negative 0.1%-1% 1.7% 2.4% 3.3% Het met 0% 0% 0%
12 (1983) Positive 0% 0% 0% 0% 1%-10% 18.9% 33.0% 53.6%
13 (1983) Negative 1%-10% 19.0% 27.0% 30.8% 0% 0% 0% 0%
14 (1983) Negative 0.1%-1% 0.8% 2.5% 6.3% Het met 0.2% 0.4% 1.4%
15 (1983) Negative 0% 0%
0%
0% 0% 0.1%-1% 0.3% 0.9% 5.1%
16 (1988) Negative 0% 0% 0% 0% Het met 0.4% 0.8% 1.3%
17 (1988) Negative 0% 0% 0% 0% 10%-100% 93.3% 114.9% 186.6%
18 (1988) Negative 0% 0% 0% 0% Failed ampl 0% 0% 0%
19 (1988) Negative 1%-10% 3.4% 5.8% 10.9% Het met 0.2% 0.8% 3.8%
20 (1988) Negative 10%-100% 12.5% 14.4% 21.8% 0% 0% 0% 0%
21 (1988) Positive 0% 0% 0% 0% Het met 0.1% 0.5% 2.4%
22 (1988) Positive 0% 0% 0% 0% Het met 2.2% 2.7% 3.8%
23 (1988) Negative 10%-100% 18.9% 20.3% 21.7% 0% 0% 0% 0%
24 (1988) Negative 10%-100% 9.5% 14.4% 15.4% Het met 0.1% 0.2% 0.7%
25 (1988) Negative 10%-100% 6.3% 7.7% 10.9% 0% 0% 0% 0%
26 (1988) Negative 0% 0% 0% 0% Het met 0.2% 0.3% 0.6%
27 (1988) Negative 10%-100% 12.5% 14.4% 15.4% Failed ampl 0% 0% 0%
28 (1988) Positive 0% 0% 0% 0% 0% 0% 0% 0%
29 (1993) Negative 1%-10% 3.6% 5.8% 7.7% 0% 0% 0% 0%
30 (1993) Positive 0% 0% 0% 0% 1%-10% 2.9% 8.8% 14.4%
31 (1993) Negative 0% 0% 0% 0% Het met 0.3% 0.7% 1.4%
32 (1993) Negative 10%-100% 21.8% 26.8% 30.8% 0.1%-1% 0.1% 0.3% 0.7%
33 (1993) Negative 0% 0% 0% 0% 0% 0% 0% 0%
34 (1993) Negative 10%-100% 25.0% 40.6% 61.6% 1%-10% 2.9% 5.4% 8.8%
35 (1993) Positive 0% 0% 0% 0% Het met 0.3% 0.6% 0.8%
36 (1993) Negative 10%-100% 5.1% 10.9% 17.7% 0.1%-1% 0.2% 0.6% 1.4%
37 (1993) Positive 0% 0% 0% 0% 1%-10% 23.3% 25.0% 28.7%
38 (1993) Positive 0% 0% 0% 0% 0% 0% 0% 0%
39 (1998) Negative 0.1%-1% 0% 0% 0% 0% 2.5% 2.9% 3.4%
40 (1998) Negative 0.1%-1% 0.1% 0.1% 0.2% Het met 0.6% 1.5% 3.1%
41 (1998) Negative 10%-100% 19.0% 23.3% 28.7% 0% 0% 0% 0%
42 (1998) Positive 0% 0.1% 0.3% 0.7% Het met 0.2% 0.4% 1.4%
43 (1998) Positive 0% 0% 0% 0% 0% 0% 0% 0%
44 (1998) Positive 0.1%-1% 0.1% 0.2% 0.4% Het met 2.9% 3.6% 5.4%







0.1%-1% 0.2% 0.7% 2.9%BMC Cancer 2009, 9:453 http://www.biomedcentral.com/1471-2407/9/453
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Chi-squared test (p-value = 0.001192)). Two samples, for
which the MS-HRM and SMART-MSP did not give the
same methylation status, were omitted from the analysis.
Variation amongst bisulfite modifications
As the variation among bisulfite modifications previously
has been thoroughly evaluated using various PCR-based
methods for single locus methylation detection [27,28],
we bisulfite modified a subset of the samples a second
time, and tested for CDKN2A  methylation using MS-
HRM. Results obtained after the second bisulfite modifi-
cation were identical to the results obtained by the first
bisulfite modification.
Discussion
DNA derived from FFPE tissue represents a highly valua-
ble source of material for retrospective studies. However,
DNA derived from FFPE tissue is often highly degraded,
and for certain cancer types a limited amount of tumor tis-
sue may be available. When studying DNA methylation
changes by PCR-based methods, it is necessary to modify
the DNA with sodium bisulfite for preservation of the
46 (1998) Positive 0% 0% 0% 0% 0.1%-1% 0% 0% 0%
47 (1998) Positive 0% 0% 0% 0% 10-100% 21.8% 30.8% 50.0%
48 (1998) Positive 0% 0% 0% 0% Failed ampl 0% 0% 0%
49 (2003) Positive 0% 0% 0% 0% 0% 0% 0% 0%
50 (2003) Positive 0% 0% 0% 0% Het met 0.5% 1% 2.1%
51 (2003) No data 0% 0% 0% 0% 0% 0% 0% 0%
52 (2003) Positive 0.1%-1% 0.4% 0.6% 1.0% 1%-10% 2.7% 3.9% 5.1%
53 (2003) Negative 10%-100% 2.7% 6.3% 16.5% 1%-10% 4.1% 10.2% 26.8%
54 (2003) Negative 0% 0% 0% 0% 0% 0% 0% 0%
An average methylation estimate as well as the highest and lowest possible methylation estimates calculated from the Ct-values of the triplicates for 
the gene and the control is given for SMART-MSP.
Table 2: Methylation levels of the samples as estimated by MS-HRM and SMART-MSP.  (Continued)
Melting profiles indicating that the DNA is heterogeneously methylated at the RARB promoter Figure 3
Melting profiles indicating that the DNA is heterogeneously methylated at the RARB promoter. If molecules, in 
which different CpG positions are methylated and unmethylated are amplified, the observed melting profile will be complex. 
These different molecules will form heteroduplexes and homoduplexes after the PCR and prior to the HRM step. The very 
early melting observed is likely to be the melting of various heteroduplexes. The intermediate and later melting are likely to be 
the melting of various homoduplexes with those having the highest number of CpG positions methylated melting the latest. 
The 100% methylated standards are indicated in red, the 10% methylated standards in blue, the 1% methylated standards in 
green, the 0.1% methylated standards in brown, the 0% methylated standard in orange and non template controls are indicated 
in black. A sample (in triplicate) judged to be heterogeneously methylated is indicated in turquoise.BMC Cancer 2009, 9:453 http://www.biomedcentral.com/1471-2407/9/453
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DNA methylation information of the original template.
This treatment may further damage the DNA. Also, it is
likely that the DNA becomes even more fragmented with
age of storage.
Here, we have evaluated whether we could use sodium
bisulfite treated DNA derived from FFPE tissue from
NSCLC patients dating five to 30 years back in time for
DNA methylation analysis. Two methodologies, SMART-
MSP and MS-HRM, were used to assess the methylation
status of each of the 54 samples available for this study.
Both methods are highly sensitive and capable of measur-
ing methylation levels.
Assays targeting the promoter CpG islands of the
CDKN2A and RARB genes were designed to evaluate the
quality of the samples since aberrant methylation of these
genes is implicated in NSCLC [29], and especially
CDKN2A has shown promising results as a biomarker for
early detection [30].
Reproducibility of the methylation estimates for the FFPE samples by SMART-MSP Figure 4
Reproducibility of the methylation estimates for the FFPE samples by SMART-MSP. Plots of the absolute differ-
ence between the highest and lowest possible methylation estimate divided by the average methylation estimate against the age 
of the samples for each gene are shown. A. The CDKN2A assay. B. The RARB assay. It is observed that the overall reproducibil-
ity is better for the CDKN2A assay compared to the RARB assay. It can also be observed that the reproducibility did not depend 
on the age of the samples.
CDKN2A (p16) expression in NSCLC Figure 5
CDKN2A (p16) expression in NSCLC. A. A case in which immunohistochemical staining for p16 showed positive nuclear 
and cytoplasmic staining (×100). B. A case in which the invading tumor cells did not express p16 (×100).BMC Cancer 2009, 9:453 http://www.biomedcentral.com/1471-2407/9/453
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The methylation status of all 54 samples could be deter-
mined for both genes using SMART-MSP, even in the old-
est samples. When using MS-HRM, all samples could be
scored for CDKN2A methylation, but five samples could
not be scored for RARB methylation due to failed amplifi-
cation in at least two of three replicates. This may be due
to the fact that the MS-HRM RARB amplicon is almost
twice as long as the SMART-MSP RARB  amplicon (see
Table 1). For all amplifiable samples a highly significant
correlation was observed between the methylation esti-
mates provided by each method.
One sample was estimated to be methylated above 100%
at the RARB promoter by SMART-MSP. Methylation esti-
mates relative to in vitro methylated DNA may occasion-
ally be obtained for heavily methylated genes because the
calibrator (positive control) may not be 100% methylated
in spite of extensive SssI treatment [31].
We observed a tendency for the RARB promoter to be het-
erogeneously methylated. It was only possible to examine
whether the DNA was heterogeneously methylated, when
using MS-HRM as the SMART-MSP assays are designed
only to amplify fully methylated molecules. The samples
were scored as being heterogeneously methylated, when
showing melting profiles characteristic for the amplifica-
tion of molecules of different methylation content
[13,24].
The reproducibility of the SMART-MSP assays could be
expected to be less satisfactory for the older samples. To
investigate this hypothesis we plotted the absolute differ-
ence between the highest and lowest possible methylation
estimate for the methylated samples divided by the aver-
age methylation estimate against the age of the samples
for each gene. From these plots it was clear that the repro-
ducibility did not decrease with the age of the samples
(Figure 4). Therefore, we have, for the first time, showed
the robustness of SMART-MSP and MS-HRM for methyla-
tion analysis of DNA extracted from FFPE tissue being up
to 30 years old. The reproducibility was higher for the
CDKN2A  SMART-MSP assay compared to the RARB
SMART-MSP assay. This may be explained by the tendency
for the RARB promoter to be heterogeneously methylated
in the samples we have tested.
Furthermore, we have evaluated whether immunohisto-
chemical staining of the p16 protein correlated with
methylation status of the CDKN2A (p16) gene. A highly
significant correlation was found (p-value = 0.001192),
and all methylated samples except two, which were meth-
ylated at very low levels, were found to be negative.
Twelve of 30 unmethylated samples were also negative by
immunohistochemistry. This may be due to homozygous
deletion of the CDKN2A (p16) gene, which often is found
in NSCLC [32].
A recent study has assessed the quality of archival FFPE tis-
sue for DNA methylation studies using MS-HRM and
MethyLight [27]. A high concordance between the MS-
HRM and MethyLight results was observed, and a high
reproducibility in between different runs and bisulfite
modifications was found. However, no information of the
age of the FFPE tissue was provided.
The methylation assays we have developed analyze the
same CpG positions in two different ways, using the same
real-time PCR and HRM instrument. In spite of the innate
differences of the two types of assays, we have shown that
similar methylation estimates can be obtained. For this
reason, a more accurate and reliable methylation estimate
may be obtained when using both SMART-MSP and MS-
HRM.
Conclusions
In conclusion, DNA from FFPE tissue can be successfully
used for methylation studies in spite of being 30 years old
when using MS-HRM or SMART-MSP. These two method-
ologies are closed-tube, very sensitive, and require no flu-
orescent probes. Since MS-HRM and SMART-MSP can be
performed on the same instrument, a more accurate
methylation estimate can be achieved in the samples of
interest, as each method verifies the results of the other.
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